- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01690819
Protective Ventilatory Strategy in Severe Acute Brain Injury (PROLABI)
Protective Ventilatory Strategy in Severe Acute Brain Injury: Randomized Multi-center Controlled Trial
Acute respiratory distress syndrome (ARDS) occurs in almost 20% of patients with severe acute brain injury and is associated with increased morbidity and mortality. A massive increase in sympathetic activity and an increased production of proinflammatory cytokines released into the systemic circulation are the most important recognized mechanisms. Altered blood brain barrier after injury causes spillover of inflammatory mediators from the brain into the systemic circulation leading to peripheral organs damage. The adrenergic surge induces an increase in vascular hydrostatic pressure and lung capillary permeability, causing an alteration of alveolar capillary barrier with fluid accumulation, resulting in ARDS.
The main goal of mechanical ventilation after acute brain injury are the maintenance of optimal oxygenation, and a tight control of carbon dioxide tension, although ventilatory settings to be used to obtain these targets, while avoiding secondary insults to the brain, are not clearly identified.
Protective ventilatory strategy has been positively evaluated first in patients with ARDS, and then in those undergoing cardiopulmonary bypass or lung resection surgery, or in brain death organ donors, but data on the effect of protective mechanical ventilation on patients with acute brain injury are still lacking even if this is a population with recognized risk factors for ARDS.
Therefore, the primary aim of this multi-center, prospective, randomized, controlled trial is to investigate whether a protective ventilatory strategy, in the early phase after severe acute brain injury, is associated with a lower incidence of ARDS, avoiding any further damage to the brain. Secondary aim is to evaluate if a protective ventilatory strategy is associated with reduced duration of mechanical ventilation, incidence of organ failure, intensive care unit length of stay, and lower concentrations of plasma inflammatory cytokines, without adversely affect in neurological outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND Acute respiratory distress syndrome (ARDS) is described as the most common non-neurologic organ dysfunction occurring in the early phase after severe acute brain injury, with a reported incidence of 10-15% and increased morbidity and mortality.
A significant role has been recently proposed for neuro-inflammation in the genesis of ARDS following acute brain injury. The neuro-inflammatory response represents initially a coordinated effort to protect the brain after injury, but may then become altered and be responsible for the activation of the secondary injury cascade leading to single or multiple organ dysfunction. This preclinical event may increase the susceptibility of lungs to the stress of injurious mechanical ventilation. The main targets of ventilatory management of acute brain injury patients are maintenance of an optimal oxygenation, and a tight arterial carbon dioxide control. Actual Guidelines for the management of severe traumatic brain injury, in particular, state that hypoxia (PaO2 <60 mmHg or SaO2 < 90%) should be avoided and PaCO2 level tightly controlled with a target of 35-38 mmHg. However, no published recommendation exists on which ventilator setting, in terms of tidal volume, respiratory rate, and positive end-expiratory pressure (PEEP) levels, should be used to obtain these respiratory targets. In previous studies on patients with ARDS, mechanical ventilation with a low tidal volume and moderate PEEP levels resulted in decreased mortality and increased number of ventilatory free days, and it now represents the standard of care for these patients.
Patients with acute brain injury represent a category at risk to develop ARDS both because of the adrenergic cascade and the inflammatory reaction, and because of the ventilatory strategy implemented to optimize gas exchange. Nevertheless, no clinical trial has been performed to evaluate the effect of protective ventilatory strategies upon severe acute brain injury patients.
AIMS The aim of this study is to investigate whether the application of a protective ventilatory strategy, defined as low tidal volume and moderate levels of PEEP, improves the combined end point of "event free survival" defined as survival without ventilator dependency or ARDS diagnosis, without adversely affecting neurological outcome.
Secondary aim of this study is to evaluate if protective ventilatory strategy may increase number of ventilator and organ failure free days, reduce intensive care unit (ICU) length of stay, reduce the incidence of ventilator associated pneumonia (VAP), reduce concentrations of plasma inflammatory cytokines (IL-6, TNF-alpha, TNF-RI/II, IL-8, IL-1ra, IL-1beta), without adversely affecting neurological outcome as measured by the Modified Oxford Handicap scale at intensive care unit discharge and the Glasgow Outcome Scale-extended (GOSe) at 6 months.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Turin, Italy, 10126
- University of Turin - Department of Anesthesia and Intensive Care Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with severe acute brain injury (traumatic brain injury, subarachnoid haemorrhage, intra-cerebral haemorrhage, and ischemic stroke)
- Patients with not obey commands and do not open eyes on GCS (Glasgow Coma Scale)
- Less than 24 hours of mechanical ventilation (expected >72 hours)
Exclusion Criteria:
- Age < 18 years
- Diagnosis of ARDS before randomization.
- Patients unlikely to survive for the next 24 hours in the opinion of ICU consultant.
- Pregnancy
- Post-anoxic coma
- Metabolic or toxic encephalopathy
- Lack of Informed Consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Conventional Ventilatory Strategy
|
The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
|
EXPERIMENTAL: Protective Ventilatory Strategy
Protective ventilatory strategy
|
The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of event free survival
Time Frame: 28 days
|
Combined end point of "event free survival" defined as survival without ventilator dependency or ARDS* diagnosis *ARDS will be defined according to Berlin definition criteria. If chest x-ray is not immediately available, ARDS diagnosis will be suspected and confirmed later on. Interpretation of bilateral infiltrates on chest x-ray and of heart failure vs. fluid overload was variable and in a large observational study (LUNGSAFE, JAMA. 2016 Feb 23;315:788-800) hypoxemic patients with new infiltrates were described as a well-defined group with outcome, risk factors, comorbidities and clinical management similar to ARDS. Therefore, in March 2016 the study protocol replaced "ARDS" with "acute hypoxemic respiratory failure" as one of the components of the composite primary endpoint. Acute hypoxemic respiratory failure was defined as PaO2/FiO2 ratio < 300, with presence of infiltrates on chest x-ray, independently of lung opacities distribution and characteristics. |
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of ventilator free days at 28 days
Time Frame: 28 days
|
28 days
|
|
number of ICU free days at day 28 after randomization
Time Frame: participants will be followed for the duration of ICU stay, an expected average of 3 weeks
|
participants will be followed for the duration of ICU stay, an expected average of 3 weeks
|
|
Incidence of ventilator associated pneumonia (VAP)
Time Frame: 28 days
|
28 days
|
|
Cumulative SOFA free score from the randomization to day 28
Time Frame: 28 days
|
28 days
|
|
Concentrations of plasma inflammatory cytokines
Time Frame: 7 days
|
7 days
|
|
Modify Oxford Handicap Scale at ICU discharge
Time Frame: participants will be followed for the duration of ICU stay, an expected average of 3 weeks
|
participants will be followed for the duration of ICU stay, an expected average of 3 weeks
|
|
Glasgow Outcome Scale extended (GOSe) at 6 months
Time Frame: at 6 months
|
at 6 months
|
|
Mortality at day 28 after randomization
Time Frame: 28 days
|
28 days
|
|
LOS in ICU
Time Frame: 20 days (average time)
|
length of stay in intensive care unit
|
20 days (average time)
|
Hospital length of stay (HLOS)
Time Frame: 30 days (average time)
|
length of stay in hospital
|
30 days (average time)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROLABI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Injuries, Acute Brain
-
Massachusetts General HospitalCompletedAcute Brain InjuriesUnited States
-
University Hospital, Clermont-FerrandOrion Corporation, Orion PharmaUnknown
-
Kendra Jorgensen-WagersThe Defense and Veterans Brain Injury CenterUnknown
-
Joanne Kurtzberg, MDM.D. Anderson Cancer Center; Emory University; The Marcus FoundationCompletedStroke | Stroke, Acute | Brain Injury, AcuteUnited States
-
CentraCareElectroCore INCCompletedTraumatic Brain Injury | Acute Brain InjuriesUnited States
-
Nantes University HospitalRecruitingNon Traumatic Neuro-Vascular Diseases Critical Complications : a Prospective Cohort Study (ATLANREA)Non Traumatic Acute Brain InjuryFrance
-
The University of Texas Health Science Center,...United States Department of Defense; U.S. Army Medical Research and Development...Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, AcuteUnited States
-
University of California, Los AngelesSuspended
-
University of RostockUnknown
-
Mario Negri Institute for Pharmacological ResearchRecruiting
Clinical Trials on Conventional Ventilatory Strategy
-
M.D. Anderson Cancer CenterRecruiting
-
China National Center for Cardiovascular DiseasesUnknown
-
Hospital Universitario 12 de OctubreRecruitingSubstrate abLatIon as Concomitant trEatment for Left Atrial Macroreentrant Tachycardia (SLICE-LAMRT)Atrial FibrillationSpain
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Centre Hospitalier Universitaire DijonRecruitingFocal Acute Respiratory Distress SyndromeFrance
-
Affiliated Hospital of Nantong UniversityEnrolling by invitationTumor MicroenvironmentChina
-
Rui WangCompletedRespiratory Distress Syndrome, AdultChina
-
Azienda Ospedaliero Universitaria Maggiore della...CompletedSurgery | Atelectasis | Artificial RespirationItaly
-
St. Justine's HospitalRecruitingHeart Defects, Congenital | Tetralogy of Fallot | Univentricular Heart | Hypoplastic Left Heart SyndromeCanada
-
University Hospital, BordeauxEIT HealthActive, not recruitingVentricular TachycardiaFrance, Germany, Switzerland, Austria